TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Among TAVR patients with AFib, DOACs lead to better survival rates than vitamin K antagonists

However, the two treatment options were associated with similar rates of long-term bleeding and ischemic events. 

Thumbnail

New meta-analysis compares early TAVR outcomes for Sapien 3, Evolut valves—and spots some key differences

The new study focused on the early outcomes of more than 24,000 patients who participated in a total of nine different studies.

Thumbnail

Embolic protection devices fail to limit death or stroke among TAVR patients

The meta-analysis, published in the American Journal of Cardiology, explored data from six different randomized trials. 

Thumbnail

American College of Cardiology shares new guidance on TAVR-related conduction disturbances

The new guidance was designed to help clinicians provide high-quality care before, during and after TAVR procedures. 

Thumbnail

Medtronic announces 2 new TAVR studies, including a head-to-head comparison of Evolut Pro and Sapien 3

A new feasibility study focused on additional patient populations is also in the works.

Thumbnail

Valve durability after 5 years: Sapien 3 TAVR outcomes comparable to SAVR

The Sapien 3 prosthesis continues to impress, though researchers must continue to monitor its performance as time goes on.

Thumbnail

TAVR safe for low-risk patients with bicuspid aortic valve disease

More research on long-term outcomes is still needed before TAVR can be recommended for such patients across the board.

Thumbnail

How COVID-related delays are impacting TAVR patients

Some high-risk patients died during the delay, the research team reported. 

Displaying 377 - 384 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.